Otonomy Inc. buy melinda
Start price
30.08.17
/
50%
€3.87
Target price
13.11.17
€7.00
Performance (%)
33.23%
End price
13.11.17
€5.15
Summary
This prediction ended on 13.11.17 with a price of €5.15. The BUY prediction by melinda for Otonomy Inc. saw massive gains of 33.23%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Otonomy Inc. | - | - | - | - |
| iShares Core DAX® | 1.301% | -1.386% | 12.259% | 59.752% |
| iShares Nasdaq 100 | 0.612% | -4.172% | 1.687% | 86.147% |
| iShares Nikkei 225® | 8.772% | 9.777% | 30.041% | 63.047% |
| iShares S&P 500 | 0.254% | -2.301% | 0.794% | 57.981% |
Comments by melinda for this prediction
In the thread Otonomy Inc. diskutieren
30. August (Reuters) - US - Arzneimittelhersteller Otonomy Inc. sagte am Mittwoch , dass seine Droge Meniere-Krankheit, eine chronische Erkrankung des Innenohrs zu behandeln, das Hauptziel in einer späten Studie fehlt.